Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07150793 · ClinicalTrials.gov registry record
A Study of Real-world Treatment and Burden of Chronic Myeloid Leukemia Patients in Japan
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 754
- Enrollment target
NCT07150793: Completed study, sponsored by Novartis Pharmaceuticals.
NCT07150793 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 754 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07150793 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 754 participants
- Enrollment target
Study Summary
The main goal of this study was to describe treatment patterns of patients with chronic myeloid leukemia (CML) who were treated with tyrosine kinase inhibitors (TKIs) in Japan. This was a retrospective observational study with secondary use of data from the Medical Data Vision (MDV) hospital-based database. The index date was the date of the first prescription of any TKI of interest registered within the selection period (01 January 2011 to 31 December 2019). The follow-up period was from the index date until the end of the study period, end of continuous follow-up in the MDV database, or death, whichever came first.
Primary Outcome
TKIs included imatinib, bosutinib, dasatinib, nilotinib, and ponatinib.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 754 participants |
| Start Date | 2022-07-05 |
| Est. Completion | 2023-02-08 |
What the finished NCT07150793 record still lists
NCT07150793 is an observational study that tracks outcomes without assigning an intervention. The registered 754 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT07150793 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07150793 about?
NCT07150793 is a clinical study titled "A Study of Real-world Treatment and Burden of Chronic Myeloid Leukemia Patients in Japan". The main goal of this study was to describe treatment patterns of patients with chronic myeloid leukemia (CML) who were treated with tyrosine kinase inhibitors (TKIs) in Japan. This was a retrospective observational study with secondary use of data from the Medical Data Vision (MDV) hospital-based ...
What is the current status of trial NCT07150793?
This trial is currently completed. The enrollment target is 754 participants. The study started on 2022-07-05. Estimated completion is 2023-02-08.
Who is sponsoring clinical trial NCT07150793?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05379985 · 754 participants · Phase 1
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- NCT05427370 · 754 participants · NA
The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)
- NCT05869149 · 756 participants · NA
Systems Science Approaches to Improve Access to Healthier Foods: The FRESH Trial
- NCT06095583 · 756 participants · Phase 3
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI